Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-13

  Hatakeyama, Hiromitsu ^a   Cheng, Haixia ^b   Wirth, Pamela ^a   Counsell, Ashley ^a   Marcrom, Samuel R ^a   Wood, Carey Burton ^a   Pohlmann, Paula R ^a   Gilbert, Jill ^a   Murphy, Barbara ^a   Yarbrough, Wendell G ^a   Wheeler, Deric L ^c   Harari, Paul M ^c   Guo, Yan ^a,d   Shyr, Yu ^d   Slebos, Robbert J ^a   Chung, Christine H ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MICRORNA; MICRORNA 212; UNCLASSIFIED DRUG; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; MIRN212 MICRORNA, HUMAN; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION REGULATION; GENE INTERACTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HEAD AND NECK TUMOR; METABOLISM; TUMOR CELL LINE; UPREGULATION;

ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICRORNAS; UP-REGULATION;

EID: 77958520234     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012702     Document Type: Article

References (47)

1. Arteaga C (2003) Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 30: 3-14.
2. Harris R, Chung E, Coffey R (2003) EGF receptor ligands. Experimental Cell Research 2003. pp 2-13.
3. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
4. Cullen BR (2004) Transcription and processing of human microRNA precursors. Mol Cell 16: 861-865.
5. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U (2004) Nuclear export of microRNA precursors. Science 303: 95-98.
6. Hammond SM, Bernstein E, Beach D, Hannon GJ (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404: 293-296.
7. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114.
8. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
9. Grandis J, Melhem M, Gooding W, Day R, Holst V, et al. (1998) Levels of TGFalpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832.
10. Cohen EEW, Rosen F, Stadler WM, Recant W, Stenson K, et al. (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 21: 1980-1987.
11. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, et al. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77-85.
12. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
13. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127.
14. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
15. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655.
16. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, et al. (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237.
17. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
18. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, et al. (2005) Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11: 8105-8108.
19. Bissada E, Abou-Chacra Z, Weng X, Guertin L, Nguyen-Tan P, et al. (2008) Prevalence of K-RAS codon 12 mutations in locally advanced head and neck squamous cell carcinoma and influence with regards to response to chemoradiation therapy. J Clin Oncol 26: abstr: 17005.
20. Licitra L, Rolland F, Bokemeyer C, Remenar E, Kienzer H, et al. (2009) Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN. J Clin Oncol 27: abstr: 6005.
21. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene.
22. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, et al. (1984) Monoclonal antiepidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7760.
23. Erbitux® (cetuximab) prescribing information. ImClone Systems, Inc. 2006, New York, NY 10014 and Bristol-Myers Squibb Company, Princeton, NJ 08543; October 2007.
24. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, et al. (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769-779.
25. Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JM, et al. (2009) Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res 15: 2397-2405.
26. Smith JP, Pozzi A, Dhawan P, Singh AB, Harris RC (2009) Soluble HB-EGF induces epithelial-to-mesenchymal transition in inner medullary collecting duct cells by upregulating Snail-2. Am J Physiol Renal Physiol 296: F957-965.
27. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733.
28. Chan E, LaFleur B, Rothenberg ML, Merchant N, Lockhart AC, et al. (2010) Dual blockade of the EGFR and COX-2 pathways: A phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am J Clin Oncol In press.
29. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
30. Iwamoto R, Mekada E (2006) ErbB and HB-EGF signaling in heart development and function. Cell Struct Funct 31: 1-14.
31. Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, et al. (1995) Phorbol ester induces the rapid processing of cell surface heparin-binding EGFlike growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 6: 967-980.
32. Raab G, Klagsbrun M (1997) Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1333: F179-199.
33. Iwamoto R, Handa K, Mekada E (1999) Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor. J Biol Chem 274: 25906-25912.
34. Nanba D, Mammoto A, Hashimoto K, Higashiyama S (2003) Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 163: 489-502.
35. Nanba D, Higashiyama S (2004) Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor. Cytokine Growth Factor Rev 15: 13-19.
36. Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, et al. (2003) Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci U S A 100: 3221-3226.
37. Shirakata Y, Kimura R, Nanba D, Iwamoto R, Tokumaru S, et al. (2005) Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing. J Cell Sci 118: 2363-2370.
38. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, et al. (1999) Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126: 2739-2750.
39. Troyer KL, Luetteke NC, Saxon ML, Qiu TH, Xian CJ, et al. (2001) Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-alpha. Gastroenterology 121: 68-78.
40. Yagi H, Yotsumoto F, Miyamoto S (2008) Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther 7: 3441-3451.
41. Wang F, Sloss C, Zhang X, Lee SW, Cusack JC (2007) Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res 67: 8486-8493.
42. Wang F, Liu R, Lee SW, Sloss CM, Couget J, et al. (2007) Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 26: 2006-2016.
43. Thomson S, Buck E, Petti F, Griffin G, Brown E, et al. (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65: 9455-9462.
44. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698.
45. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, et al. (2007) Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6: 1683-1691.
46. Chung CH, Parker JS, Ely K, Carter J, Yi Y, et al. (2006) Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-{kappa}B Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma. Cancer Res 66: 8210-8218.
47. Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, et al. (2007) MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 358: 12-17.